CNS involvement in Mantle-cell lymphoma

被引:57
|
作者
Montserrat, E
Bosch, F
LopezGuillermo, A
Graus, F
Terol, MJ
Campo, E
Rozman, C
机构
[1] UNIV BARCELONA,HOSP CLIN,DEPT NEUROL,E-08036 BARCELONA,SPAIN
[2] UNIV BARCELONA,HOSP CLIN,DEPT PATHOL,E-08036 BARCELONA,SPAIN
关键词
D O I
10.1200/JCO.1996.14.3.941
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In non-Hodgkin's lymphomas, CNS involvement is highly dependent on the histology of the lymphoma, Mantle-cell lymphoma (MCL) is a lymphoma type with distinctive histologic, biologic, and clinical features in which CNS involvement has only been rarely described. The purpose of this report is to describe the incidence, clinical characteristics, and outcome of CNS infiltration in patients with MCL seen at a single institution. Patients and Methods: Twenty-two patients with MCL, who account for 6% of all patients with nodal lymphomas diagnosed and monitored at a university hospital from 1987 to 1994, were studied. Analysis of the incidence of CNS involvement by the disease was performed. Results: Five of 22 patients (22%; exact 95% confidence interval [CI], 7.8% to 45.4%) with MCL developed CNS involvement at a median of 18 months (range, 6 to 59) from diagnosis, All of these patients presented with poor MCL histologic subtypes and advanced disease, When the CNS infiltration became apparent, all of the patients displayed neurologic signs and had lymphoid cells consistent with the diagnosis of MCL in the CSF, In most of the cases, CNS infiltration was part of resistant disease or generalised relapse and had an ominous significance. Conclusion: The incidence of CNS involvement in MCL might be higher than previously recognized. The frequency of CNS infiltration in MCL deserves to be investigated in other series and, if a high incidence is confirmed, the risk factors, mechanisms, and clinical implications of such a complication should be further studied. (C) 1996 by American Society of Clinical Oncology,
引用
收藏
页码:941 / 944
页数:4
相关论文
共 50 条
  • [1] Mantle-Cell Lymphoma
    Yavorkovsky, Leonid L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (11): : 1049 - 1050
  • [2] MANTLE-CELL LYMPHOMA
    DEWOLFPEETERS, C
    PITTALUGA, S
    ANNALS OF ONCOLOGY, 1994, 5 : S35 - S37
  • [3] Mantle-cell lymphoma
    Chen, J
    Swerdlow, SH
    Jacobs, SA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) : 2568 - 2569
  • [4] Mantle-Cell Lymphoma
    Armitage, James O.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (26): : 2495 - 2506
  • [5] Mantle-cell lymphoma
    Barista, Ibrahim
    Romaguera, Jorge E.
    Cabanillas, Fernando
    LANCET ONCOLOGY, 2001, 2 (03): : 141 - 148
  • [6] Mantle-cell lymphoma
    Campo, E
    Raffeld, M
    Jaffe, ES
    SEMINARS IN HEMATOLOGY, 1999, 36 (02) : 115 - 127
  • [7] Mantle-cell lymphoma
    Sun, WM
    Chotiprasidhi, P
    Finn, W
    GASTROINTESTINAL ENDOSCOPY, 2005, 61 (07) : 875 - 875
  • [8] IS THERE A HIGH-RISK FOR CENTRAL-NERVOUS-SYSTEM (CNS) INVOLVEMENT IN MANTLE-CELL LYMPHOMA (MCL)
    MONTSERRAT, E
    LOPEZGUILLERMO, A
    BOSCH, F
    TEROL, MJ
    CAMPO, E
    ROZMAN, C
    BLOOD, 1994, 84 (10) : A645 - A645
  • [9] Diagnosis in oncology - Bilateral panocular involvement with mantle-cell lymphoma
    Chappelow, Aimee V.
    Singh, Arun D.
    Perez, Victor L.
    Lichtin, Alan
    Pohlman, Brad
    Macklis, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1167 - 1167
  • [10] Mantle-cell lymphoma of colon
    Kram, MT
    Olsen, DA
    Lo, W
    GASTROINTESTINAL ENDOSCOPY, 2005, 61 (02) : 294 - 295